IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
IDEAYA completed its first NDA submission in Q3 2026 for the darovasertib plus crizotinib combination in metastatic uveal melanoma, filed under the FDA's Real-Time Oncology Review program. ESMO 2026 data supported darovasertib across primary and metastatic uveal melanoma regardless of HLA-A*02:01 status, while Hengrui's Phase 1 data for IDE849 showed a 17.4-month median OS in 2L SCLC, with two IDE849 Phase 3 registrational trials planned to start by year end. In a notable setback, IDEAYA is closing the Phase 3 OptimUM-010 trial due to site activation and enrollment challenges, redirecting an estimated $100-125 million in savings to other programs including IDE849 and IDE892.
Key figures
- Revenue
- 10242000
- Guidance
- Cash runway guidance into 2030 unchanged based on current operating plan
- Net loss
- 125749000
- Ga expense
- 26298000
- Rnd expense
- 121576000
- Cash and investments
- 1150827000
- Optimum010 cost savings usd m
- 100-125
- Optimum011 planned enrollment
- 450
- Ide849 2l sclc median os months
- 17.4
- Optimum09 eye preservation rate
- 57%
- Es sclc phase3 planned enrollment
- 400
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.